Back to search results

Proton Therapy for Liver Metastases

This study is looking at how safe and effective proton therapy is for treating liver metastases (cancers that have spread to the liver from another part of the body). Proton therapy is a type of radiation that precisely targets tumors. All patients in this study will receive proton radiation in 3 sessions over no more than 14 days, with different dose levels being tested. The main goal is to see how many participants experience side effects. You may be able to join if you are 18 or older, have 1 to 3 liver lesions (tumors) that are less than 5cm, and have a life expectancy of more than 6 months. The study aims to enroll 35 participants.

Study design
This study is an interventional study with an unclear phase, aiming to enroll 35 participants. It is testing different dose levels of proton radiation.
What's involved
Participants will receive 3 fractions (treatment sessions) of proton radiation within a 14-day period. The initial results will be analyzed after each patient has been followed for at least 3 months.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for a minimum of 3 months after treatment to assess safety and tolerability.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT01697371

Proton Therapy in the Treatment of Liver Metastases

Recruiting
NAAges 18+InterventionalTreatment
Loma Linda University
~35 participants
Updated 2026-06-05 on ClinicalTrials.gov
What's tested:ProtonProton Radiation

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Phase I of study: Number of participants with adverse events as a measure of safety and tolerability
Measured over The major analysis for reporting the initial results of treatment will be undertaken when each patient has been potentially followed for a minimum of 3 months

Conditions

Liver Metastases

Explore related trials

Metastatic Malignant Neoplasm in the Liver

NCT01697371

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Loma Linda University Medical Center

    Loma Linda, Californiano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

Who to contact

Proton Referral Office First Call: Referral Office intake personnel
909-558-4288 or 1 800 PROTONS
Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3 based upon CBC/differential obtained within 4 weeks prior to registration on study
Platelets ≥ 60,000 cell/mm3 based upon CBC/differential obtained within 4 weeks prior to registration on study
Hemoglobin ≥ 8.0 g/dl based upon CBC/differential obtained within 4 weeks prior to registration on study (Note: the use of transfusion or other intervention to achieve Hgb ≥ 8.0 is acceptable.)
A complete history and general physical examination
For women of childbearing potential, a serum or urine pregnancy test must be performed within 72 hours prior to registration
INR, total bilirubin, albumin, alkaline phosphatase, ALT, AST within 4 weeks prior to study entry

What this trial measures

  • Phase I of study: Number of participants with adverse events as a measure of safety and tolerabilityThe major analysis for reporting the initial results of treatment will be undertaken when each patient has been potentially followed for a minimum of 3 months